Create an account or log in to participate in this activity
This activity was planned in collaboration with the Federation of State Medical Boards.
In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Boston University Chobanian & Avedisian School of Medicine designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Contact Hours: 2, of which 2 are eligible for pharmacology credit
This program meets the criteria of the Massachusetts Board of Registration in Medicine for risk management study and opioid education. Several states have similar requirements. Please check with your Board to determine if this activity will fulfill your state's specific requirements.
This program meets the criteria of the Massachusetts Board of Registration in Medicine for risk management study.
This program meets the criteria of the Massachusetts Board of Registration in Medicine for opioid education.
The AAFP has reviewed SCOPE of Pain: Safer/Competent Opioid Prescribing Education and deemed it acceptable for up to 2.00 Enduring Materials, Self-Study AAFP Prescribed credits. Term of Approval is from 03/01/2024 to 03/01/2025. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.
This activity is approved for 2.0 CPE credit(s) under the ACPE universal activity number UAN JA0000185-0000-24-025-H08-P. The activity is available for credit claiming for up to 60 days after completion of the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate and de-identified data is shared with the commercial supporters.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
By participating in the activity and claiming credit, you grant the Center for Continuing Education permission to submit your information to the ACCME, the conduit to the ABS.
Through the American Board of Medical Specialties (ABMS) ongoing commitment to increase access to practice relevant Maintenance of Certification (MOC) Activities through the ABMS Continuing Certification Directory, SCOPE of Pain has met the requirements as an MOC Part II Self-Assessment and/or MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:
Note: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board's general CME requirement (only). Please refer directly to your Member Boards' MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
In order to receive credit, participants must review the activity content and complete the post-tests and evaluation for the two one-hour modules included within the activity. Participants who receive a cumulative grade of 70% or greater on the post-tests will receive credit. BOTH of the one-hour modules must be completed in order to earn your online certificate of credit. There will also be an online follow-up survey that will be distributed two months after completion of the program in order to further measure participant's changes in knowledge and behavior.
Date of Release: 10/1/2024
Date of Expiration: 9/30/2025
Physicians, nurse practitioners, registered nurses, physician assistants, nurses, dentists, pharmacists, and allied health professionals whose practices manage acute and chronic pain.
At the conclusion of these activities, participants will be better able to:
For questions about CME, please contact cme@bu.edu or www.bu.edu/cme.
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships with ineligible companies that faculty, planners, authors and anyone who may be in control of content have been mitigated.
This activity does include discussion of the off-label use of certain formulations of buprenorphine to treat pain. These formulations are approved to treat opioid use disorder but not to treat pain. This presentation does include discussion of the off-label use of clonidine and tizanidine to treat opioid withdrawal symptoms. Clonidine and tizanidine are not FDA approved for this use.
Faculty members and planning committee members listed below have no relevant financial relationships to disclose.
Daniel P. Alford, MD, MPH (Course Director)
Professor of Medicine
Associate Dean, Continuing Medical Education
Director, Clinical Addiction Research and Education (CARE) Unit
Boston University Chobanian & Avedisian School of Medicine | Boston Medical Center
Erica Bial, MD, MS
Interventional Pain Specialist, Private Practice
Faculty, Tufts University, Medford, Massachusetts
Faculty members have no relevant financial relationships to disclose.
Patrick Kelly, PharmD, University of Rhode Island College of Pharmacy, Pharmacist Advisor
Kristin Wason, NP, Boston University Chobanian & Avedisian School of Medicine | Boston Medical Center, Nurse Advisor
Brian Jack, MD, Independent AAFP reviewer
Jason Worcester, MD, Boston University Chobanian & Avedisian School of Medicine, Independent CME reviewer
Ilana Hardesty, MA, Assistant Director, Boston University Chobanian & Avedisian School of Medicine
Content development and planning committee members have no relevant financial relationships to disclose.
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).
This additional module is required for users licensed in the State of New York: "Managing Pain and Opioid Use: An Educational Program on Compliance with New York State Prescribing Laws."
There is a $25 fee for the NY module.
SCOPE of Pain
© 2024 Trustees of Boston University. Site by Root802.
Overview